THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.31] ID: TIP-MED-000263 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Naloxone Hydrochloride (Parenteral Opioid Overdose Antidote)

Active Ingredient / Scientific Identity: Naloxone Hydrochloride • Class: Pure Competitive Opioid Receptor Antagonist (Mu, Kappa & Delta Antidote)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Naloxone Hydrochloride (Parenteral Opioid Overdose Antidote) ([12.31] | ID: TIP-MED-000263) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/12-31-naloxone-hydrochloride-parenteral-opioid-overdose-antidote/
Generic / Entity NameNaloxone Hydrochloride (Parenteral Opioid Overdose Antidote) ([12.31])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassPure Competitive Opioid Receptor Antagonist (Mu, Kappa & Delta Antidote)
Available Dosage FormsInjection: 400 mcg/mL (0.4 mg/mL) in 1 mL ampoule; Neonatal Injection: 20 mcg/mL (0.02 mg/mL).
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No adjustment required. • Hepatic: No adjustment required in emergency reversal.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Naloxone Hydrochloride (Parenteral Opioid Overdose Antidote) (TIP-MED-000263, Reference Code [12.31]) is classified under Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Pure Competitive Opioid Receptor Antagonist (Mu, Kappa & Delta Antidote). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.31], p. 170): Nex, Narcotan, Nalox — Strengths & Dosage Forms: Injection: 400 mcg/mL (0.4 mg/mL) in 1 mL ampoule; Neonatal Injection: 20 mcg/mL (0.02 mg/mL).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.31], p. 170): Nex, Narcotan, Nalox — Strengths & Dosage Forms: Injection: 400 mcg/mL (0.4 mg/mL) in 1 mL ampoule; Neonatal Injection: 20 mcg/mL (0.02 mg/mL).
Dosage Forms & Available Strengths:
Injection: 400 mcg/mL (0.4 mg/mL) in 1 mL ampoule; Neonatal Injection: 20 mcg/mL (0.02 mg/mL).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Competitively displaces opioid agonists from CNS mu (greatest affinity), kappa, and delta opioid receptors without intrinsic agonist activity -> restores central respiratory drive within 1–2 minutes (IV).

4. Therapeutic Indications & Evidence-Supported Uses

  • Emergency reversal of opioid-induced respiratory depression and coma (morphine, fentanyl, tramadol, buprenorphine, heroin, codeine overdose)
  • diagnostic differentiation of suspected acute opioid coma

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Acute Opioid Overdose (Apnoea/Severe Respiratory Depression): Start 0.4–2 mg IV (or IM/SC if no IV access); repeat every 2–3 minutes up to 10 mg if no response. Post-Operative Opioid Reversal (to restore respiration without abolishing analgesia): Dilute 0.4 mg (1 mL) in 9 mL 0.9% NaCl (= 40 mcg/mL) and titrate 100–200 mcg (2.5–5 mL) IV every 2 minutes. • Paediatric: Opioid Overdose: 0.1 mg/kg IV (up to 20 kg) or 2 mg IV (>20 kg). Post-op reversal: 1–10 mcg/kg IV titrated.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No adjustment required. • Hepatic: No adjustment required in emergency reversal.
Elimination & Renal Adjustment:
Renal: No adjustment required. • Hepatic: No adjustment required in emergency reversal.
Hepatic Impairment Considerations:
Renal: No adjustment required. • Hepatic: No adjustment required in emergency reversal.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Known hypersensitivity to naloxone (none in life-threatening apnoeic overdose). • Precautions: CRITICAL PHARMACOKINETIC MISMATCH ('RE-NARCOTISATION'): Naloxone has a short elimination half-life (30–90 minutes), which is MUCH shorter than most opioids (Morphine 3-4h, Methadone 24-36h, Fentanyl patches, Buprenorphine)—patients who wake up after a single Naloxone bolus frequently lapse back into fatal respiratory arrest 45–60 minutes later! Observe for >=4–6 hours (24h for long-acting opioids) and start a continuous IV infusion (hourly rate = 2/3 of the effective waking bolus). In opioid-dependent patients, large boluses trigger explosive acute withdrawal, catecholamine surge, pulmonary oedema, and ventricular arrhythmias.

Key Clinical Precautions: Renal: No adjustment required. • Hepatic: No adjustment required in emergency reversal.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Acute opioid withdrawal syndrome in dependent patients (restlessness, diaphoresis, vomiting, tachycardia, hypertension, severe pain).
  • Flash non-cardiogenic pulmonary oedema, hypertensive crisis, ventricular fibrillation, seizures.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Reverses all opioid analgesia; Buprenorphine (high-affinity partial agonist) and high-dose Fentanyl analogues require higher Naloxone doses (2-10 mg) for reversal

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Warn revived patients against leaving the hospital against medical advice (AMA), explaining that the antidote wears off in 45 minutes while the opioid remains in the body.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Injection: 400 mcg/mL (0.4 mg/mL) in 1 mL ampoule; Neonatal Injection: 20 mcg/mL (0.02 mg/mL).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.31] (p. 170)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/12-31-naloxone-hydrochloride-parenteral-opioid-overdose-antidote/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.